Principia Wealth Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Principia Wealth Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.12K	Hold	5	–	–	﹤0.01%	470
2026 Q1	$3.86K	Hold	5	–	–	﹤0.01%	353
2025 Q4	$3.86K	Buy	5 +2	+67%	+$1.36K	﹤0.01%	321
2025 Q3	$1.69K	Hold	3	–	–	﹤0.01%	478
2025 Q2	$1.57K	Hold	3	–	–	﹤0.01%	440
2025 Q1	$1.73K	Hold	3	–	–	﹤0.01%	306
2024 Q4	$2.14K	Buy	+3	New	+$2.52K	﹤0.01%	235

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Principia Wealth Advisory's REGN Position: Q2 2026 in Review

Principia Wealth Advisory held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 5 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Principia Wealth Advisory first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.86K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Principia Wealth Advisory held 5 shares of Regeneron Pharmaceuticals worth $3.12K as of Q2 2026.
Principia Wealth Advisory left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #470 holding.
Principia Wealth Advisory first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Principia Wealth Advisory's Regeneron Pharmaceuticals position peaked at $3.86K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.